全文获取类型
收费全文 | 562407篇 |
免费 | 51199篇 |
国内免费 | 21603篇 |
专业分类
耳鼻咽喉 | 3896篇 |
儿科学 | 12424篇 |
妇产科学 | 7486篇 |
基础医学 | 85397篇 |
口腔科学 | 11203篇 |
临床医学 | 48948篇 |
内科学 | 88177篇 |
皮肤病学 | 7653篇 |
神经病学 | 38573篇 |
特种医学 | 13586篇 |
外国民族医学 | 166篇 |
外科学 | 47829篇 |
综合类 | 85231篇 |
现状与发展 | 81篇 |
一般理论 | 25篇 |
预防医学 | 33169篇 |
眼科学 | 10977篇 |
药学 | 62508篇 |
118篇 | |
中国医学 | 21618篇 |
肿瘤学 | 56144篇 |
出版年
2023年 | 6847篇 |
2022年 | 10300篇 |
2021年 | 18898篇 |
2020年 | 17857篇 |
2019年 | 18908篇 |
2018年 | 18391篇 |
2017年 | 19092篇 |
2016年 | 19916篇 |
2015年 | 21832篇 |
2014年 | 33175篇 |
2013年 | 37460篇 |
2012年 | 33107篇 |
2011年 | 37827篇 |
2010年 | 31720篇 |
2009年 | 30644篇 |
2008年 | 30471篇 |
2007年 | 30798篇 |
2006年 | 28044篇 |
2005年 | 25365篇 |
2004年 | 21774篇 |
2003年 | 18940篇 |
2002年 | 14999篇 |
2001年 | 13815篇 |
2000年 | 11440篇 |
1999年 | 10055篇 |
1998年 | 7596篇 |
1997年 | 6951篇 |
1996年 | 6182篇 |
1995年 | 6196篇 |
1994年 | 5503篇 |
1993年 | 4581篇 |
1992年 | 3962篇 |
1991年 | 3452篇 |
1990年 | 2897篇 |
1989年 | 2514篇 |
1988年 | 2314篇 |
1987年 | 1871篇 |
1986年 | 1618篇 |
1985年 | 2524篇 |
1984年 | 2572篇 |
1983年 | 1755篇 |
1982年 | 2005篇 |
1981年 | 1637篇 |
1980年 | 1440篇 |
1979年 | 1191篇 |
1978年 | 954篇 |
1977年 | 753篇 |
1976年 | 770篇 |
1975年 | 604篇 |
1974年 | 461篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
2.
目的分析同型半胱氨酸(Hcy)、溶血磷脂酸(LPA)及转化生长因子-β1(TGF-β1)在创伤性骨折下肢静脉栓塞中的预测价值。方法选取2019年3月至2020年2月商丘市第一人民医院收治的104例创伤性骨折者(观察组),根据有无DVT:有DVT组33例,无DVT组71例;根据创伤严重程度:轻度组61例,重度组43例。另选取本院同期92例健康体检者设为对照组。比较不同人群、不同病情程度以及有无DVT者血浆Hcy、LPA及血清TGF-β1水平,分析Hcy、LPA及TGF-β1对DVT的预测价值。结果观察组Hcy、LPA及TGF-β1表达水平均明显高于对照组,差异均有统计学意义(P<0.05)。重度组Hcy、LPA及TGF-β1表达水平明显高于轻度组,差异均有统计学意义(P<0.05)。有DVT组者Hcy、LPA及TGF-β1表达水平明显高于无DVT组,差异均有统计学意义(P<0.05)。依据ROC曲线分析可知,Hcy+LPA+TGF-β1三者联合预测创伤性骨折后发生DVT敏感度和特异度分别为88.90%、8130%,明显高于三者单独检测(P<0.05)。结论Hcy、LPA及TGF-β1在创伤性骨折发生下肢静脉栓塞时水平均明显升高,三者联合检测对下肢静脉栓塞早期诊断有重要的临床价值。 相似文献
3.
4.
5.
6.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
7.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
8.
9.
10.
Biaoming Xu Yu Chen Mingjing Peng Jin Hai Zheng Chaohui Zuo 《International journal of cancer. Journal international du cancer》2023,152(2):110-122
Pancreatic cancer (PC) is a cancer of the digestive system, and pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all PC cases. Exosomes derived from PDAC (PDAC-exosomes) promote PDAC development and metastasis. Exosomes are nanoscale vesicles secreted by most cells, which can carry biologically active molecules and mediate communication and cargo transportation among cells. Recent studies have focused on transforming exosomes into good drug delivery systems (DDSs) to improve the clinical treatment of PDAC. This review considers PDAC as the main research object to introduce the role of PDAC-exosomes in PDAC development and metastasis. This review focuses on the following two themes: (a) the great potential of PDAC-exosomes as new diagnostic markers for PDAC, and (b) the transformation of exosomes into potential DDSs. 相似文献